US healthcare giant Johnson & Johnson (J&J) has reached agreement to buy Swiss biotech company Actelion in a $30bn (€28bn) all-cash deal that includes spinning off Actelion’s research and development pipeline, the companies said yesterday.
From our friends over at the : IrishExaminer.com Business
You can see the Full Story: Click Here